Aspirin for Venous Ulcers: Randomised Trial (AVURT): study protocol for a randomised controlled trial

Helen Tilbrook, Rachael O Forsythe, Debbie Rolfe, Laura Clark, Martin Bland, Hannah Buckley, Ian Chetter, Liz Cook, Jo Dumville, Rhian Gabe, Keith Harding, Alison Layton, Ellie Lindsay, Catriona McDaid, Christine Moffatt, Ceri Phillips, Gerard Stansby, Peter Vowden, Laurie Williams, David Torgerson, Robert J Hinchliffe, Helen Tilbrook, Rachael O Forsythe, Debbie Rolfe, Laura Clark, Martin Bland, Hannah Buckley, Ian Chetter, Liz Cook, Jo Dumville, Rhian Gabe, Keith Harding, Alison Layton, Ellie Lindsay, Catriona McDaid, Christine Moffatt, Ceri Phillips, Gerard Stansby, Peter Vowden, Laurie Williams, David Torgerson, Robert J Hinchliffe

Abstract

Background: Venous leg ulcers (VLUs) are the commonest cause of leg ulceration, affecting 1 in 100 adults. There is a significant health burden associated with VLUs - it is estimated that the cost of treatment for 1 ulcer is up to £1300 per year in the NHS. The mainstay of treatment is with graduated compression bandaging; however, treatment is often prolonged and up to one quarter of venous leg ulcers do not heal despite standard care. Two previous trials have suggested that low-dose aspirin, as an adjunct to standard care, may hasten healing, but these trials were small and of poor quality. Aspirin is an inexpensive, widely used medication but its safety and efficacy in the treatment of VLUs remains to be established.

Methods/design: AVURT is a phase II randomised double blind, parallel-group, placebo-controlled efficacy trial. The primary objective is to examine whether aspirin, in addition to standard care, is effective in patients with chronic VLUs (i.e. over 6 weeks in duration or a history of VLU). Secondary objectives include feasibility and safety of aspirin in this population. A target of 100 participants, identified from community leg ulcer clinics and hospital clinics, will be randomised to receive either 300 mg of aspirin once daily or placebo. All participants will receive standard care with compression therapy. The primary outcome will be time to healing of the reference ulcer. Follow-up will occur for a maximum of 27 weeks. The primary analysis will use a Cox proportional hazards model to compare time to healing using the principles of intention-to-treat. Secondary outcomes will include ulcer size, pain evaluation, compliance and adverse events.

Discussion: The AVURT trial will investigate the efficacy and safety of aspirin as a treatment for VLU and will inform on the feasibility of proceeding to a larger phase III study. This study will address the paucity of information currently available regarding aspirin therapy to treat VLU.

Trial registration: The study is registered on a public database with clinicaltrials.gov ( NCT02333123 ; registered on 5 November 2014).

References

    1. NICE Clinical Knowledge Summaries. Leg ulcer – venous. . Accessed 16 July 2015.
    1. Ashby RL, Gabe R, Ali S, Adderley U, Bland MJ, Cullum NA, et al. Clinical and cost-effectiveness of compression hosiery versus compression bandages in treatment of venous leg ulcers (Venous leg Ulcer Study IV, VenUS IV): a randomised controlled trial. Lancet. 2014;383(9920):871–9. doi: 10.1016/S0140-6736(13)62368-5.
    1. de Araujo T, Valencia I, Federman DG, Kirsner RS. Managing the patient with venous ulcers. Ann Intern Med. 2003;138(4):326–34. doi: 10.7326/0003-4819-138-4-200302180-00012.
    1. Barwell JR, Davies CE, Deacon J, Harvey K, Minor J, Sassano A, et al. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial. Lancet. 2004;363(9424):1854–9. doi: 10.1016/S0140-6736(04)16353-8.
    1. Iglesias C, Nelson EA, Cullum NA, Torgerson DJ, VenUS Team VenUS I: a randomised controlled trial of two types of bandage for treating venous leg ulcers. Health Technol Assess. 2004;8(29):iii. doi: 10.3310/hta8290.
    1. Abbade LPF, Lastória S, de Rollo HA. Venous ulcer: clinical characteristics and risk factors. Int J Dermatol. 2011;50(4):405–11. doi: 10.1111/j.1365-4632.2010.04654.x.
    1. Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. The accuracy of venous leg ulcer prognostic models in a wound care system. Wound Repair Regen. 2004;12:163–8. doi: 10.1111/j.1067-1927.2004.012207.x.
    1. O’Meara S, Cullum N, Nelson EA, Dumville JC. Compression for venous leg ulcers (Review) Cochrane Library. 2014;11:1–196.
    1. Herber OR, Schnepp W, Rieger MA. A systematic review on the impact of leg ulceration on patients’ quality of life. Health Qual Life Outcomes. 2007;5(1):44. doi: 10.1186/1477-7525-5-44.
    1. Salome GM, de Brito MJA, Ferreira LM. Impact of compression therapy using Unna’s boot on the self-esteem of patients with venous leg ulcers. J Wound Care. 2014;23(9):442–6. doi: 10.12968/jowc.2014.23.9.442.
    1. Tennvall GR, Hjelmgren J. Annual costs of treatment for venous leg ulcers in Sweden and the United Kingdom. Wound Repair Regen. 2005;13(1):13–8. doi: 10.1111/j.1067-1927.2005.130103.x.
    1. Lim CS, Davies AH. Pathogenesis of primary varicose veins. Br J Surg. 2009;96(11):1231–42. doi: 10.1002/bjs.6798.
    1. Scottish Intercollegiate Guidelines Network. SIGN 120. Management of chronic venous leg ulcers. A national clinical guideline. . 2010.
    1. O’Meara S, Cullum NA. Compression for venous leg ulcers. Cochrane Database Syst Rev. 2009;1:CD000265.
    1. Nelson EA, Iglesias CP, Cullum N, Torgerson DJ. Randomized clinical trial of four-layer and short-stretch compression bandages for venous leg ulcers (VenUS I) Br J Surg. 2004;91(10):1292–9. doi: 10.1002/bjs.4754.
    1. Madden M. The ghost of Nora Batty: a qualitative exploration of the impact of footwear, bandaging and hosiery interventions in chronic wound care. Chronic Illness. 2015;0(0):1–12.
    1. Ashby RL, Gabe R, Ali S, Saramago P, Chuang L-H, Adderley U, et al. VenUS IV (Venous leg Ulcer Study IV) – compression hosiery compared with compression bandaging in the treatment of venous leg ulcers: a randomised controlled trial, mixed-treatment comparison and decision-analytic model. Health Technol Assess. 2014;18(57):1–293. doi: 10.3310/hta18570.
    1. O’Meara S, Richardson R, Lipsky BA. Topical and systemic antimicrobial therapy for venous Leg ulcers. JAMA. 2014;311(24):2534–5. doi: 10.1001/jama.2014.4574.
    1. Jull AB, Arroll B, Parag V, Waters J. Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev. 2012;12:CD001733.
    1. Nelson EA, Prescott RJ, Harper DR, Gibson B, Brown D, Vaughan RC. A factorial, randomized trial of pentoxifylline or placebo, four-layer or single-layer compression, and knitted viscose or hydrocolloid dressings for venous ulcers. J Vasc Surg. 2007;45(1):134–41. doi: 10.1016/j.jvs.2006.09.043.
    1. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110(5–6):255–8. doi: 10.1016/S0049-3848(03)00379-7.
    1. Ibbotson SH, Layton AM, Davies JA, Goodfield MJ. The effect of aspirin on haemostatic activity in the treatment of chronic venous leg ulceration. Br J Dermatol. 1995;132(3):422–6. doi: 10.1111/j.1365-2133.1995.tb08676.x.
    1. Layton AM, Ibbotson SH, Davies JA, Goodfield M. Randomized trial of oral aspirin for chronic venous Leg ulcers. Lancet. 1994;344(8916):164–5. doi: 10.1016/S0140-6736(94)92759-6.
    1. del Rio Sola ML, Antonio J, Fajardo G, Vaquero PC. Influence of aspirin therapy in the ulcer associated with chronic venous insufficiency. Ann Vasc Surg. 2012;26(5):620–9. doi: 10.1016/j.avsg.2011.02.051.
    1. Gohel MS, Barwell JR, Taylor M, Chant T, Foy C, Earnshaw J, et al. Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial. BMJ. 2007;335(7610):83–7. doi: 10.1136/.
    1. Marrocco CJ, Atkins MD, Bohannon WT, Warren TR, Buckley CJ, Bush RL. Endovenous ablation for the treatment of chronic venous insufficiency and venous ulcerations. World J Surg. 2010;34(10):2299–304. doi: 10.1007/s00268-010-0659-1.
    1. Kirsner RS, Nole KLB, Fox JD, Liu SN. Healing refractory venous ulcers: new treatments offer hope. J Investig Dermatol. 2015;135(1):19–23. doi: 10.1038/jid.2014.444.
    1. Zuloff-Shani A, Adunsky A, Even-Zahav A, Semo H, Orenstein A, Tamir J, et al. Hard to heal pressure ulcers (stage III-IV): efficacy of injected activated macrophage suspension (AMS) as compared with standard of care (SOC) treatment controlled trial. Arch Gerontol Geriatr. 2010;51(3):268–27. doi: 10.1016/j.archger.2009.11.015.
    1. Da Costa RM, Ribeiro Jesus FM, Aniceto C, Mendes M. Randomized, double-blind, placebo-controlled, dose-ranging study of granulocyte-macrophage colony stimulating factor in patients with chronic venous leg ulcers. Wound Repair Regen. 1999;7(1):17–25. doi: 10.1046/j.1524-475X.1999.00017.x.
    1. Mostow EN, Haraway GD, Dalsing M, Hodde JP, King D, Grp OVUS. Effectiveness of an extracellular matrix graft (OASIS wound matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg. 2005;41(5):837–43. doi: 10.1016/j.jvs.2005.01.042.
    1. Jones JE, Nelson EA, Hity AA. Skin grafting for venous leg ulcers. Chichester, UK: Wiley; 2013.
    1. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119(8):624–38. doi: 10.1016/j.amjmed.2005.10.039.
    1. Antithrombotic Trialists’ (ATT) Collaboration. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60. doi: 10.1016/S0140-6736(09)60503-1.
    1. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321(7270):1183–7. doi: 10.1136/bmj.321.7270.1183.
    1. FDA US Department of Health and Human Services Food and Drug Administration. Guidance for industry chronic cutaneous ulcer and burn wounds – developing products for treatment. . 2006. Accessed 16th July 2015.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir